3. F1174 mutations have a higher transforming capacity than R1275 mutations.
Introduction
Neuroblastoma is the most common solid extracranial pediatric tumor with an annual incidence of 1 in 100 000 children below the age of 15 years (1) . Despite intensive multimodal treatment, neuroblastoma remains fatal in almost half of the unfavorable patients. Insights into the molecular pathogenesis of this disease are required for the development of less toxic and more effective molecular targeted therapy. Detailed studies of patterns of DNA copy number alterations have been instrumental in our understanding of the clinical and biological heterogeneity of this tumor. Three major genomic subtypes represent more than 80% of all cases, i.e. hyperploid neuroblastoma with whole chromosome gains and losses, near diploid neuroblastoma with 11q deletions and 17q gain, and MYCN amplified neuroblastoma with 1p deletions and 17q gain (2) (3) (4) (5) . The discovery of rare but recurrent high level amplification of the ALK gene and a genetic study of familial neuroblastomas led to the discovery of activating ALK mutations in neuroblastoma (6) (7) (8) (9) (10) . The frequency of ALK mutations in primary neuroblastoma varied between 6% and 11% in the different studies (6) (7) (8) (9) (10) . The relatively low number of mutations described in each of the individual studies has precluded a thorough analysis of the frequency and distribution of recurrent ALK mutations across the different genomic subtypes. Moreover, in the first published series, there was a significant bias towards analysis of high stage tumors, thus preventing a more general assessment of frequency and distribution of mutations across different stages (6) (7) (8) . In our current study, we screened an additional 254 neuroblastoma cases including all clinical stages and genomic subtypes. In a meta-analysis, these findings were combined with those from 455 published cases (8) (9) (10) for which genomic subtype and clinical information were available. This strategy enabled us to analyze the ALK mutation profile in relation to genomic subtypes for 455 published tumors screened for ALK mutations were retrieved from the publications or made available by the authors (supplementary Table 1 ) (8) (9) (10) . In addition, 39 neuroblastoma cell lines were included. The cell lines were obtained from several sources (see supplementary Table 2 ). All of the cell lines were genotyped by DNA fingerprinting (PowerPlex, Promega).
Genomic DNA was isolated using the Qiagen DNA isolation kit (Qiagen) or a standard proteinase K/SDS procedure.
ALK DNA sequence analysis
For the first tumor cohort (146 cases) and the 39 cell lines, all 29 ALK coding exons were analyzed, whereas the remaining 108 tumors were screened for only the tyrosine kinase domain. Constitutional DNA from blood samples was available and analyzed for 12 of the 17 patients with a mutation in the primary tumor. Exons were amplified from genomic DNA (primer information in supplementary Table 3 ). PCR products were subjected to directional or bidirectional sequencing using BigDye Terminator V1.1/V3.1 Cycle Sequencing chemistry on an ABI3730XL sequencer (Applied Biosystems). Electropherograms were analyzed using Seqscape v2.5 software (Applied Biosystems).
Research. were performed on sets of tumors profiled on the same platform. For Kaplan-Meier and log-rank analysis, ALK expression levels were digitalized using the median expression value as cut-off.
Research. 
Tissue micro-array and immunohistochemistry
For the establishment of a tissue micro-array, three representative areas from each tumor were selected on H&E stained slides from 70 formalin-fixed and paraffinembedded primary untreated neuroblastoma tumors (supplementary Table 4 The medium score of the three punches was calculated for Kaplan-Meier and logrank analysis. 
Western blotting
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Transformation assay
Ba/F3 cells were cultured in RPMI-1640 supplemented with 10% FBS and 1ng/mL murine IL-3 (Peprotech). ALK F1174L and ALK R1275Q constructs were generated by PCR, cloned into the retroviral vector pMSCV-neo (Clontech) and transduced in 
Statistical analysis
Fisher's exact tests, Mann-Whitney tests and correlation analyses were performed using R (version 2.8.1). The R Survival package was used to generate Kaplan-Meier plots and to perform log-rank analyses. Multivariate logistic regression analysis was performed using the glm function (R-base package).
Research.
on 
Results
ALK mutation analysis in 254 primary neuroblastoma tumors and 39 neuroblastoma cell lines
In a series of 254 sporadic, non-familial primary neuroblastoma tumors, a total of 17 ALK mutations (6.7%) and 2 ALK amplifications (0.8%) were identified (supplementary Figure 1) . In a first series of 146 cases, all 29 ALK coding exons were analyzed but no mutations were found outside the tyrosine kinase domain.
Therefore, only the tyrosine kinase domain was analyzed for the remaining 108
tumors. The most frequent mutations were located at residues R1275 and F1174 and were detected in respectively 3.9% (10/254) and 2.0% (5/254) of the cases. A third recurrent but less frequent mutation affecting residue F1245 (6-9) was not detected in our series. One of the mutations previously reported in only one tumor was also detected as a single case in our series (Y1278S) (10), thus providing further evidence for its contribution to neuroblastoma pathogenesis. In addition to the previously reported mutations we observed one new missense mutation, R1231Q. Sequence analysis of the constitutional DNA of 12 out of 17 patients with an ALK mutation showed that these mutations were somatically acquired.
Mutation analysis was also performed in 39 neuroblastoma cell lines. All mutations, except for one (D1091N in LAN-6), were exclusively found within the tyrosine kinase domain. Recurrent mutations were found in two cell lines that were previously not analyzed, STA-NB-8 and NB-14. All results of previously reported cell lines were in concordance with published results except for one (see supplementary Table 1 ).
Research. Table 2 ).
Frequency of ALK mutations according to genomic subtype
To further explore the relationship between ALK mutation status and genomic alterations, we classified the tumors into genomic subclasses based on arrayCGH data (3 Figure 1B) .
Correlation of ALK mutation with survival
No significant survival differences were found in tumors with or without ALK mutations (or amplifications) (log-rank P=.317) (Figure 2A ). However, when comparing survival of patients with R1275 mutation or wild-type patients with patients with the F1174 mutation type, Kaplan-Meier analysis showed significant survival differences (P=.027 and P=.002) ( Figure 2B and 2C ). This might largely be explained by the high frequency of MYCN amplification within the F1174 mutated tumors compared to the R1275 mutated tumors.
ALK immunoreactivity
In addition to the relation between ALK transcript expression and survival, we also investigated the ALK protein expression status and patient survival using a tissue micro-array (TMA) containing 70 primary tumors. Kaplan-Meier and log-rank analysis 
Transforming capacity of ALK hot-spot mutations
Given the observed concordance between mutation type and ALK activity, we also compared the transforming capacity of both ALK hotspot mutations in IL-3 dependent Ba/F3 cell lines.
on Of further interest in this context is the observation that F1174 mutations in the germline have not been reported up to now, which could suggest embryonic lethality.
Of particular interest was the observation that only one of the 10 patients with MYCN amplification together with a F1174 mutation survived, in contrast to a 32% 5-year overall survival rate in patients with MYCN amplified tumors without the F1174 mutation.
The different distribution across the genomic subtypes and the adverse impact of the F1174 mutations on survival raise the question whether the F1174 and R1275
mutations may execute distinct effects on tumor biology. George and colleagues have previously also shown that both F1174L and R1275Q mutants could transform Ba/F3 cells, but their analysis did not reveal major differences in oncogenic potential between these two mutants, in part because the proliferation data were not reported in detail. In our hands, the F1174L mutant transformed the Ba/F3 cells more efficiently than the cells expressing the R1275Q mutant. This correlated with higher auto-phosphorylation levels of ALK FL, which was not observed for the RQ mutant.
Occurrence of mutations of particular genes in relation to genomic subgroups have been reported in certain tumor entities such as PIK3CA mutations in head and neck squamous carcinomas without EGFR amplification and beta-catenin mutations in medulloblastomas with loss of chromosome 6 (18) (19) (20) . However, to the best of our knowledge, a different distribution for mutations within the same functional domain of one specific gene, as observed here for the F1174 mutation in ALK, has not been reported.
Our study also showed, in contrast to some of the initial studies, that ALK mutations occur in fairly equal frequency in both low and high stage tumors. Therefore, mutation 6.02E-01
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